TX-MAVENIR
11.1.2021 14:02:37 CET | Business Wire | Press release
Mavenir , the industry’s only end-to-end Network Software Provider and a leader in accelerating software network transformation for communications service providers (CSPs), has expanded and cloudified its Portfolio by announcing four new solutions: WebScale Platform, AI & Analytics, Multi-Access Edge Computing (MEC) and Digital Enablement Platform, all available today.
With cloud-native applications and technology innovation in the software space for mobile communications, consistent with Mavenir’s DNA, these solutions support the ongoing cloudification of the mobile networks, to enable CSPs to meet the growing data demands on their networks.
Mavenir’s cloud centric approach means moving applications to Commercial Off-The-Shelf (COTS) computing servers and embracing a complete ecosystem with applications in the Cloud (private, hybrid or public), which complement the basic Network Virtualized Functions (NVFs) and bring automation to improve the way operators manage and operate their networks.
In addition, this approach creates more flexibility and agility enabling the introduction of new services not only in the traditional consumer business, but also in the enterprise arena.
Webscale Platform: Suresh Somasundaram, SVP of 5G Cloud Platforms at Mavenir explains, “Mobile networks require digital transformation towards webscale platform technology that utilizes open source, Kubernetes platform as a service (PaaS). While a Kubernetes-based platform (PaaS) provides the foundation for fully automated life cycle management, it is built for mainly IT and enterprise applications and requires additional and specialized functions to support telecom and specifically, mobile workloads. To support those types of workloads, Mavenir has developed a common software extending standard opensource PaaS components to support telco needs for webscale deployment and to provide agile delivery of new applications expanding to Performance, Monitoring, Legal Intercept and Security. Mavenir’s WebScale Platform is the solution to give Mobile Operators the webscale agility of the Internet players.”
AI-powered Analytics : Kuntal Chowdhury, GM, AI & Analytics at Mavenir said, “With the cloudification and automation of the telecom networks, it becomes essential to utilize AI & Analytics solutions in a scalable platform combining real-time and big data analytics based on advanced Machine Learning algorithms. Mavenir’s AI & Analytics platform delivers extensive insights that are mandatory for WebScale network automation, slice management, security and many other use cases defined for the MEC (EdgeAI), RAN intelligence, traffic optimization and security. The AI/ML algorithms are defined with Mavenir’s deep telecom domain expertise, while keeping the interfaces standards-compliant & the platform open for collaborative innovation.”
Multi-access Edge Computing (MEC) : Ashok Khuntia, GM Cloud Packet Computing says, “Delivering low latency and high bandwidth at the edge of the network promises many exciting applications in 5G. Mavenir's optimized low-footprint data processing 5G Core platform enables mission critical MEC applications in the areas of Industrial automation, Augmented Reality/Virtual Reality, Gaming, Video surveillance, Autonomous driving and others. The additional focus on Multi-access Edge Computing (MEC) will accelerate such applications for many different industries and sectors.”
Digital Enablement: Sandeep Singh, GM, Digital Enablement at Mavenir noted, “Mavenir enables Operators and Enterprises to launch innovative value-based services faster to market with lower upfront investments in capital and time. Mavenir’s Digital Enablement Platform unlocks any network data, sources partner data, and serves up a value-added offering enriched through the platform’s flexible business control functions like Partner/Customer Management, Order Journey-Experience builder, Subscription/Usage Billing, Charging and Settlement. With the design focus on ‘adaptability’, the platform provides customers the agility and flexibility to experiment iteratively and deliver enhanced subscriber engagement experiences, ultimately benefitting in increased market reach and customer stickiness through new revenue generating services.”
“With a modern and secure Webscale platform as a foundation for edge computing, state of the art AI-based Analytics and Customer engagement solutions in our portfolio, Mavenir is a partner of choice for Telcos looking to offer new mission critical network edge solutions, transform network operations and business models for new 5G networks. In addition, Enterprises who need cost efficiency and customization in their connectivity and communication solutions will benefit,” said Bejoy Pankajakshan, Mavenir’s Chief Strategy Officer. “With a worldwide installed base and decades of experience in designing ‘Multi-G’ Telco services, Mavenir now offers its customer a path to realize the true potential of 5G through these new technology solutions.”
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native Network Software and Solutions/Systems Integration Provider, focused on accelerating software network transformation for Communications Service Providers (CSPs). Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging innovations in IMS (VoLTE, VoWiFi, Advanced Messaging (RCS)), Private Networks as well as vEPC, 5G Core and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 120 countries, which serve over 50% of the world’s subscribers.
Mavenir embraces disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005303/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom